Axsome Therapeutics, Inc.
US ˙ NasdaqGM ˙ US05464T1043

SecurityAXSM / Axsome Therapeutics, Inc.
InsiderMark E Saad
This page shows the track record and history of Saad Mark E insider trades in Axsome Therapeutics, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Mark E Saad in AXSM / Axsome Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-11-17 3,000 34.5324 3,000 34.5324 103,597 281 69.8500 105,953 102.27
2021-11-17 100 34.3950 100 34.3950 3,440
2021-11-17 100 34.4500 100 34.4500 3,445
2021-11-17 100 34.4000 100 34.4000 3,440
2019-05-23 3,500 22.3300 3,500 22.3300 78,155

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AXSM / Axsome Therapeutics, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Mark E Saad in AXSM / Axsome Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AXSM / Axsome Therapeutics, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-09-05 2025-09-05 4 Saad Mark E AXSM Common Stock S - Sale D 125.0700 -9,127 -1,142 10,002
2025-09-05 2025-09-05 4 Saad Mark E AXSM Common Stock M - Exercise D 9.0000 9,127 82 19,129
2024-09-11 2024-09-11 4 Saad Mark E AXSM Common Stock S - Sale D 91.3100 -11,016 -1,006 10,002
2024-09-11 2024-09-11 4 Saad Mark E AXSM Common Stock M - Exercise D 3.6700 11,016 40 21,018
2022-03-08 2022-03-04 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 29.91 2,337 2,337
2021-11-19 2021-11-17 4 Saad Mark E Custodial account for child AXSM Common Stock P - Purchase I 34.4000 100 3 100
2021-11-19 2021-11-17 4 Saad Mark E Custodial account for child AXSM Common Stock P - Purchase I 34.4500 100 3 100
2021-11-19 2021-11-17 4 Saad Mark E Custodial account for child AXSM Common Stock P - Purchase I 34.3950 100 3 100
2021-11-19 2021-11-17 4 Saad Mark E AXSM Common Stock P - Purchase D 34.5324 3,000 104 10,002
2021-06-08 2021-06-04 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 61.32 7,325 7,325
2021-03-09 2021-03-05 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 65.02 1,241 1,241
2020-06-05 2020-06-05 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 77.38 13,000 13,000
2020-03-19 2020-03-17 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 45.14 3,789 3,789
2019-06-10 2019-06-07 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 22.03 13,000 13,000
2019-05-24 2019-05-23 4 Saad Mark E AXSM Common Stock P - Purchase D 22.3300 3,500 78 7,002
2019-03-21 2019-03-19 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 12.95 29,387 29,387
2018-06-05 2018-06-01 4 Saad Mark E AXSM Stock Options (right to buy) A - Award D 3.45 13,000 13,000
2018-04-05 2018-03-12 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 2.85 32,602 32,602
2017-03-17 2017-03-15 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 4.95 11,000 11,000
2017-03-17 2017-03-15 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 4.95 31,346 31,346
2016-06-01 2016-05-27 4 Saad Mark E AXSM Stock Option (Right to Buy) A - Award D 8.02 6,231 6,231
2015-11-24 2015-11-24 4 Saad Mark E AXSM 8% Convertible Note A - Award D 5.94 3,502 0
2015-11-24 2015-11-24 4 Saad Mark E AXSM Common Stock C - Conversion D 5.9400 3,502 21 3,502
2015-11-23 2015-11-19 4 Saad Mark E AXSM Employee Stock Option (Right to Buy) A - Award D 9.00 9,127 9,127
P
Pasaran terbuka atau pembelian persendirian sekuriti bukan derivatif atau derivatif
S
Pasaran terbuka atau jualan persendirian sekuriti bukan derivatif atau derivatif
A
Pemberian, penganugerahan atau pemerolehan lain sekuriti daripada syarikat (seperti opsyen)
C
Penukaran derivatif
D
Penjualan atau pemindahan sekuriti kembali kepada syarikat
F
Pembayaran harga pelaksanaan atau liabiliti cukai menggunakan sebahagian daripada sekuriti yang diterima daripada syarikat
G
Hadiah sekuriti oleh atau kepada orang dalam
K
Swap ekuiti dan urus niaga lindung nilai yang serupa
M
Pelaksanaan atau penukaran sekuriti derivatif yang diterima daripada syarikat (seperti opsyen)
V
Transaksi dilaporkan secara sukarela pada Borang 4
J
Lain-lain (disertai dengan nota kaki yang menerangkan transaksi)